Remove 2023 Remove Biosimilars Remove Drug Development Remove Pharma Companies
article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

On January 31 2023, an internally circulated version of the European Commission’s overhaul of the EU’s pharma legislation was leaked, and published by Politico 1. The draft also proposes a voucher system for antibiotic development, in which vouchers will grant one extra year of RDP, transferable to other drugs or sellable.

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

This will continue to be the case going forward, but the nature of the off-patent landscape will evolve in line with ongoing changes in the segment’s ‘pipeline’: the originator products of today, which will become the generic and biosimilar medicines of tomorrow. There is significant need for more cost-effective generic versions.

article thumbnail

What is the largest CRO in the US?

Vial

By geographical region, the global CRO services market in 2023 was dominated by North America. Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market.